New combo therapy shows promise for tough melanomas
NCT ID NCT04109456
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug called IN10018, alone or with other medicines, in 51 adults with advanced melanoma that had spread. The main goal was to check safety and how the body handles the drug. The study included people with two hard-to-treat types of melanoma: uveal melanoma and NRAS-mutant melanoma.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Linear Clinical Research
Nedlands, Western Australia, Australia
-
MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
St Vincent Hospital Sydney
Sydney, New South Wales, Australia
-
Sylvester Comprehensive Cancer Center.
Miami, Florida, 33136, United States
-
The Alfred Hospital
Melbourne, Victoria, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo tame a rare eye cancer that has spread?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Can a new drug shrink Hard-to-Treat eye cancer?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?